Literature DB >> 27086810

Postprandial Reactive Hypoglycemia Treated with a Low-dose Alpha-glucosidase Inhibitor: Voglibose May Suppress Oxidative Stress and Prevent Endothelial Dysfunction.

Kunihiro Suzuki1, Daisuke Katsura, Masaaki Sagara, Chie Aoki, Mai Nishida, Yoshimasa Aso.   

Abstract

We encountered a 62-year-old woman who experienced frequent episodes of hypoglycemia. She was diagnosed with postprandial reactive hypoglycemia according to the results of oral glucose and sucrose tolerance tests, having undergone an endocrinological examination and image inspection. The administration of low-dose voglibose, an alpha-glucosidase inhibitor (α-GI), improved the glucose fluctuations and inhibited hypoglycemic symptoms. Voglibose is also known to diminish oxidative stress and maintain endothelial function after hyperglycemia. An α-GI might effectively prevent hypoglycemic symptoms and endothelial dysfunction by suppressing oxidative stress in such cases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27086810     DOI: 10.2169/internalmedicine.55.5737

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  Nocturnal reactive hypoglycaemia well treated subjectively and objectively with voglibose.

Authors:  Hiroyuki Koyama; Hideomi Ohguchi; Takashi Yagi; Kenro Imaeda
Journal:  BMJ Case Rep       Date:  2017-10-04

2.  Anti-Hyperglycemic Activity of Major Compounds from Calea ternifolia.

Authors:  Sonia Escandón-Rivera; Araceli Pérez-Vásquez; Andrés Navarrete; Mariana Hernández; Edelmira Linares; Robert Bye; Rachel Mata
Journal:  Molecules       Date:  2017-02-14       Impact factor: 4.411

3.  A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment.

Authors:  Vijaya Subramanian; Jonatan I Bagger; Jens J Holst; Filip K Knop; Tina Vilsbøll
Journal:  Front Physiol       Date:  2022-09-06       Impact factor: 4.755

4.  1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway.

Authors:  Xuehua Piao; Shuangdi Li; Xiaodan Sui; Lianyi Guo; Xingmei Liu; Hongmei Li; Leming Gao; Shusheng Cai; Yanrong Li; Tingting Wang; Baohai Liu
Journal:  Front Pharmacol       Date:  2018-04-19       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.